www.MercyCareAZ.org
January 24, 2022
Two new oral agents to treat COVID-19

Applicable To: Mercy Care Complete Care, Mercy Care Long Term Care, Mercy Care DD, Mercy Care DCS CHP, Mercy Care RBHA and Mercy Care Advantage 

Two new oral therapies have recently been approved by the FDA through Emergency Use Authorization (EUA) for COVID-19 treatment:

Paxlovid™ (nirmatrelvir/ritonavir) is indicated for adults and pediatric patients (12 years of age and older weighing at least 40kg) with positive COVID-19 test results who are at high risk for progression to severe COVID-19, including hospitalization or death.
  • AHCCCS Medicaid allows for 2 treatment courses (30 tablets per 5-day course) to be filled per year.
  • Mercy Care Advantage allows for 1 treatment course (30 tablets per 5-day course) to be filled per month.

Lagevrio® (molnupiravir) is indicated for adult patients 18 years of age and older with positive COVID-19 results who are at high risk for progression to severe COVID-19, including hospitalization or death.
  • AHCCCS Medicaid allows for 2 treatment courses (40 capsules per 5-day course) to be filled per year.
  • Mercy Care Advantage allows for 1 treatment course (40 capsules per 5-day course) to be filled per month.
  
Additionally, Mercy Care and Mercy Care Advantage cover Monoclonal antibody treatments for COVID-19. Please refer to the CDC website for the treatment guidelines at: https://www.covid19treatmentguidelines.nih.gov/.

Additional resources and guidelines are available on the ADHS website at:

Please contact your Mercy Care Network Management representative with any questions or comments. You can find this notice and all other provider notices on our Mercy Care website.

We appreciate your continued assistance, support and cooperation!
www.MercyCareAZ.org